- ￥1080 - 45885
- Prospecbio
- 以色列
- pro-508
- 2026年01月11日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
for future use below -18°C
- 保质期：
See instructions
- 英文名：
ARL1
- 库存：
常规产品有备货
- 供应商：
上海经科化学科技有限公司
- CAS号：
无
- 规格：
5ug/20ug/1mg
| 规格： | 5ug | 产品价格： | ￥1080.0 |
|---|---|---|---|
| 规格： | 20ug | 产品价格： | ￥2415.0 |
| 规格： | 1mg | 产品价格： | ￥45885.0 |
CATALOGUE NUMBER
PRO-508
SYNONYMS
INTRODUCTION
ARL1 is a weak stimulator of PLD and CT in a phospholipid dependent manner.
ARL1 is a GTP-binding protein that has low efficiency as allosteric activator of the cholera toxin catalytic subunit, an ADP-ribosyltransferase. ARL1 is involved in the Golgi apparatus.
DESCRIPTION
The ARL1 is fused to a 20 amino acid His-Tag at N-terminus and purified by proprietary chromatographic techniques.
SOURCE
PHYSICAL APPEARANCE
FORMULATION
STABILITY
For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Avoid multiple freeze-thaw cycles.
PURITY
AMINO ACID SEQUENCE
SAFETY DATA SHEET
SDS
USAGE
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验ARL1 Recombinant Human produced in E.Coli is a single, non-glycosylated polypeptide chain containing 201 amino acids (1-181 a.a.) and having a molecular mass of 22.5 kDa.
The ARL1 is fused to a 20 amino acid His-Tag at N-terminus and purified by proprietary chromatographic techniques.
Secretion of Recombinant Human Insulin-Like Growth Factor I (IGF-I)
The development of efficient recombinant protein production processes can be a critical factor in whether or not a pharmaceutical therapeutic protein can enter human clinical trials and ultimately the marketplace. This is especially true
The large number of cytokines and growth factors implicated in the regulation of liver regeneration has led to the possibility of using these molecules in therapy, namely, in the case of recombinant human hepatocyte growth factor (rhHGF
Acute myeloid leukemia (AML) has an annual incidence of 2.4 cases per 100,000 persons and is the most common form of acute leukemia in adults (1 , 2 ). AML is a model for drug-resistant human cancers, and current therapies for AML possess
技术资料